Syngene to acquire multi-modal facility from Stelis Biopharma

Adding 20,000 liters of installed biologics drug substance manufacturing capacity

Wacker Biotech partners with Caeregen Therapeutics on regenerative treatment for vision loss

As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth

Siegfried breaks ground on new R&D center for drug substances in Switzerland

The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth

Ajinomoto Bio-Pharma receives FDA approval for high potency fill line

Aji Bio-Pharma has six fill finish lines located in San Diego, including a new line

Bridgewest Group launches new sterile injectable CDMO NovaCina

Lonza and ABL Bio collaborate on development and manufacture of new bispecific antibody product

Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution

PCI Pharma plans Biologics assembly facility in the Midwest

New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies

Siegfried opens global development center for drugs in Spain

The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network

Evonik partners with AMSilk to manufacture sustainable silk proteins

Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials